Chemotherapy of lung cancer: A global perspective of the role of ifosfamide

Translational Lung Cancer Research

Volumn 1, Issue 1, 2012, Pages 61-71

  Zhou, Caicun ^a   Manegold, Christian ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Ifosfamide; Lung cancer

Indexed keywords

IFOSFAMIDE;

ARTICLE; ASIA; CANCER CHEMOTHERAPY; EUROPE; HUMAN; LUNG CANCER; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SMALL CELL LUNG CANCER; UNITED STATES;

EID: 84875452333     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2011.12.02     Document Type: Article

References (62)

1. Johnson DH. Overview of ifosfamide in small cell and nonsmall cell lung cancer. Semin Oncol 1990;17:24-30.
2. Berger DP, Fiebig HH, Winterhalter BR, et al. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo. Cancer Chemother Pharmacol 1990;26:S7-11.
3. Nemati F, Livartowski A, De Cremoux P, et al. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Clin Cancer Res 2000;6:2075-86.
4. Némati F, Daniel C, Arvelo F, et al. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anticancer Drugs 2010;21:25-32.
5. Decaudin D, de Cremoux P, Sastre X, et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005;113:849-56.
6. Kal HB, Meijnders PJ, Van Berkel AH, et al. Response to chemotherapy of non-small cell bronchial rat tumours growing subcutaneously or in the lung. In Vivo 1991;5:301-6.
7. Latz D, Schulze T, Manegold C, et al. Combined effects of ionizing radiation and 4-hydroperoxyfosfamide in vitro. Radiother Oncol 1998;46:279-83.
8. Ettinger DS, Finkelstein DM, Ritch PS, et al. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 2002;37:311-8.
9. Stahel R, Thatcher N, Früh M, et al. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011;22:1973-80.
10. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-9.
11. Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005;23:8371-9.
12. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-50.
13. Buchholz E, Manegold C, Pilz L, et al. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2007;2:51-8.
14. Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008;100:533-41.
15. Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1996;14:2337-44.
16. Hanna NH, Sandier AB, Loehrer PJ Sr, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002;13:95-102.
17. Jacot W, Pujol JL, Chakra M, et al. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. Lung Cancer 2012;75:213-6.
18. Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119-26.
19. Mukouda K, Morikawa E, Hasegawa K, et al. Ifosfamide in the treatment of small cell carcinoma of the lung. Gan To Kagaku Ryoho 1983;10:1293-8.
20. Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49:431-5.
21. Wu C, Qi H, Dai Y, et al. Therapeutic efficacy of chemotherapy with VIP for small cell lung cancer. Zhongguo Fei Ai Za Zhi 2004;7:151-3.
22. Thongprasert S. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer. J Med Assoc Thai 2000;83:549-53.
23. Woo IS, Park YS, Kwon SH, et al. A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Jpn J Clin Oncol 2000;30:542-6.
24. Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy 2003;49:200-5.
25. Fujita A, Takabatake H, Tagaki S, et al. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology 2000;59:105-9.
26. Park S, Ahn MJ, Ahn JS, et al. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 2007;58:116-22.
27. Azim HA Jr, Elattar I, Loberiza FR Jr, et al. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer 2009;64:194-8.
28. Meert AP. Stage IV NSCLC. Place of chemotherapy. Rev Mal Respir 2008;25:3S107-12.
29. Boni C, Zanelli F. Ifosfamide in non-small cell lung cancer. Oncology 2003;65:50-4.
30. Rosell R, Gómez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
31. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
32. Felip E, Rosell R, Alberola V, et al. Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial. Clin Lung Cancer 2000;1:287-93.
33. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-smallcell lung cancer. Ann Oncol 2004;15:399-409.
34. Gottfried M, Ramlau R, Krzakowski M, et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results. J Thorac Oncol 2008;3:152-7.
35. Pohl G, Krajnik G, Malayeri R, et al. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer. Lung Cancer 2006;54:63-7.
36. Takita H, Shin KH, Soh AY, et al. Induction therapy of locoregional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?). Lung Cancer 2009;63:387-92.
37. Sculier JP, Lafitte JJ, Paesmans M, et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000;83:1128-35.
38. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-30.
39. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005;23:142-53.
40. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98:542-53.
41. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006;17:1111-9.
42. Sculier JP, Lafitte JJ, Lecomte J, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV nonsmall-cell lung cancer. Ann Oncol 2002;13:874-82.
43. Baldini E, Ardizzoni A, Prochilo T, et al. Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a nonplatinum-based triplet in advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2001;85:1452-5.
44. Sharma S, Sharma R, Bhowmik KT. Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cell lung cancer. Adv Ther 2003;20:14-9.
45. Han F, Yang W, Zhu H, et al. Clinical study of ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002;5:61-3.
46. Liao G, Wang H, Qu Y, Liu P, et al. Comparison of navelbine plus ifosfamide and cisplatin versus ifosfamide plus cisplatin in the treatment of advanced non small cell lung cancer. Zhongguo Fei Ai Za Zhi 2003;6:138-40.
47. Behera D, Aggarwal AN, Sharma SC, et al. Ifosfamide containing regimen for non-small cell lung cancer. Indian J Chest Dis Allied Sci 2004;46:9-15.
48. Lin YC, Lin Y, Lin W, et al. Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer. Ai Zheng 2002;21:1359-61.
49. Han JY, Kim HK, Choi BG, et al. Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC). Jpn J Clin Oncol 1998;28:749-53.
50. Soh LT, Tan EH, Ang PT. Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. Singapore Med J 1998;39:357-8.
51. Ahn JB, Ko WK, Lee JG, et al. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer. Am J Clin Oncol 2000;23:622-8.
52. Zhao Y, Chen Y, Ji H, et al. Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2004;7:449-51.
53. Fujita A, Ohkubo T, Hoshino H, et al. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer. Br J Cancer 2003;89:1008-12.
54. Fujita A, Takabatake H, Tagaki S, et al. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colonystimulating factor support. Chest 2001;119:340-3.
55. Fujita A, Fukuoka S, Takabatake H, et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from nonsmall cell lung cancer. Oncology 2000;59:291-5.
56. Ichiki M, Rikimaru T, Gohara R, et al. Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer. Oncology 2003;64:306-11.
57. D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v116-9.
58. Lee KW, Kim YJ, Kim JH, et al. Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy. Jpn J Clin Oncol 2011;41:430-3.
59. de Castro CG Jr, de Almeida SG, Gregianin LJ, et al. Highdose chemotherapy and autologous peripheral blood stem cell rescue in a patient with pleuropulmonary blastoma. J Pediatr Hematol Oncol 2003;25:78-81.
60. Granata C, Gambini C, Carlini C, et al. Pleuropulmonary blastoma. Eur J Pediatr Surg 2001;11:271-3.
61. Lobo-Sanahuja F, García I, Santamaría S, et al. Case report: pulmonary blastoma in children-response to chemotherapy. Med Pediatr Oncol 1996;26:196-200.
62. Lindet C, Vanhuyse M, Thebaud E, et al. Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide. Acta Oncol 2011;50:156-7.